Drug news
European Commission rejects Uplyso( Pfizer/Protalix) for Gaucher Disease
The European Commission has rejected Uplyso (taliglucerase alfa ) for Gaucher Disease as a grant of approval would breach the Orphan drug status of Vpriv (velaglucerase alfa) from Shire which has 10 years exclusivity from August 2010.